Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Alessia De Stefano, BSc, Valentina Indio, PhD, Annalisa Astolfi, PhD, Andrea Pellagatti, Stefano Ratti, MD, Miriam Fogli, PhD, Sarah Parisi, MDPhD, Andrea Pession, Michele Cavo, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, Carlo Finelli

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136942

Published: 2020

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Y Follo, PhD, Andrea Pellagatti, PhD, Richard N Armstrong, PhD, Stefano Ratti, MD, Sara Mongiorgi, PhD, Annalisa Astolfi, PhD, Valentina Indio, PhD, Cristina Clissa, MD PhD, Domenico Russo, MD, Marco Gobbi, MD, Marilena Barraco, PhD, Sarah Parisi, MD PhD, Andrea Pession, MD, Michele Cavo, MD, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, PhD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 5299.

https://doi.org/10.1182/blood.V130.Suppl_1.5299.5299

Published: 2017

Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD

Blood (2016) 128 (22): 5091.

https://doi.org/10.1182/blood.V128.22.5091.5091

Published: 2016

Journal Articles

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Matilde Y Follo, PhD, Carlo Finelli, MD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Carla Filì, MD, Costanza Bosi, MD, Marilisa Quaranta, PhD, Stefania Paolini, MD, Anna Maria Billi, PhD, Marco Gobbi, MD, Michele Baccarani, MD, Domenico Russo, Giovanni Martinelli, MD, Lucia Manzoli, MD, Lucio Cocco, MD

Blood (2012) 120 (21): 1289.

https://doi.org/10.1182/blood.V120.21.1289.1289

Published: 2012

Journal Articles

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Matilde Y Follo, PhD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Francesca Chiarini, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, PhD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2011) 118 (21): 4635.

https://doi.org/10.1182/blood.V118.21.4635.4635

Published: 2011

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Francesca Chiarini, BS, Stefania Paolini, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Lucia Manzoli, MD, Alberto M. Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD, PhD

Blood (2009) 114 (22): 2384.

https://doi.org/10.1182/blood.V114.22.2384.2384

Published: 2009

NARROW

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only